|
|
Article: Schering-Plough and Novartis Sign Agreement Giving Schering-Plough U.S. Marketing Rights to FORADIL(R) AEROLIZER(R) for Respiratory Disease.
- Article from:
- PR Newswire
- Article date:
- November 1, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Schering-Plough Corporation and Novartis Pharmaceuticals Corporation, an affiliate of Novartis AG , today announced an agreement giving Schering-Plough exclusive U.S. distribution and marketing rights to Novartis' FORADIL(R) AEROLIZER(R) (formoterol fumarate inhalation powder), a selective, long-acting beta2-agonist indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), and the acute prevention of exercise-induced bronchospasm.
Under terms of the agreement, Novartis receives an upfront license payment and could receive additional payments upon the achievement of certain milestones. In addition, Schering-Plough will ...